Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBM9014
- Development stage
- Preclinical
- Lead developer
- Harbour BioMed
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
HBM9014 is a first-in-class, fully human monoclonal antibody that targets the leukemia inhibitory factor receptor (LIFR). Developed using the Harbour Mice platform by Harbour BioMed, this drug blocks multiple interleukin-6 (IL-6) family cytokine pathways via LIFR. By inhibiting these pathways, HBM9014 aims to suppress tumor progression, metastasis, and chemoresistance in cancer. Preclinical studies have demonstrated significant antitumor efficacy both as a monotherapy and in combination with cisplatin across multiple tumor models. The drug has also shown strong tolerability in primate toxicology studies[1][4][6].
02
Targets
LIFR (Leukemia inhibitory factor receptor)
Beyond the preview
Go deeper on HBM9014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBM9014.